Latest news with #THB2.66
Yahoo
04-06-2025
- Business
- Yahoo
Discover 3 Asian Penny Stocks With Market Caps Of US$400M
In the backdrop of fluctuating global trade policies and easing inflation rates, Asian markets are navigating a complex economic landscape. Amid these conditions, penny stocks—often seen as relics from past market eras—continue to capture attention for their potential to offer both affordability and growth. These smaller or newer companies can present unique opportunities when they exhibit strong financial health, making them intriguing options for investors seeking untapped potential in the market. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.26B ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.99 HK$1.66B ★★★★★★ Click here to see the full list of 1,159 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: UNQ Holdings Limited operates as a brand e-commerce retail and wholesale solutions provider in the People's Republic of China, with a market cap of HK$588.93 million. Operations: The company generates revenue through various channels, including CN¥478.70 million from B2B General Trade, CN¥421.56 million from B2C General Trade, CN¥11.58 million from services rendered, CN¥170.31 million from B2B Cross-Border E-Commerce, and CN¥266.26 million from B2C Cross-Border E-Commerce. Market Cap: HK$588.93M UNQ Holdings, with a market cap of HK$588.93 million, has shown financial improvements by becoming profitable in the past year, generating CN¥1.35 billion in sales for 2024 compared to CN¥1.74 billion previously and achieving a net income of CN¥37.89 million versus a prior net loss. Despite its low Return on Equity at 5.1%, the company maintains strong liquidity with short-term assets exceeding liabilities and cash surpassing total debt levels, indicating solid financial management amidst volatility concerns. The board's recent restructuring aligns with strategic governance adjustments as UNQ prepares to release its Q1 2025 results shortly. Click here and access our complete financial health analysis report to understand the dynamics of UNQ Holdings. Gain insights into UNQ Holdings' historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sipai Health Technology Co., Ltd. is a medical technology and health management company operating in the People's Republic of China with a market cap of HK$2.93 billion. Operations: The company's revenue is primarily derived from its Specialty Pharmacy Business, which generated CN¥3.97 billion, followed by the Physician Research Assistance Business at CN¥397.61 million, and the Health Insurance Services Business contributing CN¥192.96 million. Market Cap: HK$2.93B Sipai Health Technology, with a market cap of HK$2.93 billion, remains unprofitable despite generating CN¥4.57 billion in revenue for 2024, slightly down from the previous year. The company reported a net loss of CN¥323.74 million and has not diluted shareholders recently. Its short-term assets exceed both short- and long-term liabilities significantly, reflecting strong liquidity management alongside being debt-free. While Sipai's cash runway is sufficient for over three years if free cash flow continues to grow historically, its negative Return on Equity highlights ongoing profitability challenges amidst stable weekly volatility and an experienced management team averaging 5.7 years tenure. Unlock comprehensive insights into our analysis of Sipai Health Technology stock in this financial health report. Examine Sipai Health Technology's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ValueMax Group Limited is an investment holding company involved in pawnbroking, moneylending, jewelry and watches retailing, and gold trading primarily in Singapore, with a market capitalization of SGD528.32 million. Operations: The company's revenue is primarily derived from the retail and trading of jewellery and gold, generating SGD343.78 million, followed by pawnbroking at SGD82.01 million and moneylending contributing SGD63.46 million. Market Cap: SGD528.32M ValueMax Group, with a market cap of SGD528.32 million, has shown strong earnings growth, increasing by 56.7% over the past year, surpassing its five-year average of 19.4%. Despite high net debt to equity at 129.9%, short-term assets comfortably cover both short- and long-term liabilities. The company recently launched a digital securities issuance on the SDAX Exchange to raise funds between SGD5 million and SGD25 million at an interest rate of 3.9% per annum, reflecting active financial management strategies amidst stable weekly volatility and experienced leadership with an average tenure of 3.4 years in management and 4.8 years on the board. Click here to discover the nuances of ValueMax Group with our detailed analytical financial health report. Understand ValueMax Group's track record by examining our performance history report. Click through to start exploring the rest of the 1,156 Asian Penny Stocks now. Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2177 SEHK:314 and SGX:T6I. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
03-06-2025
- Business
- Yahoo
Discover 3 Asian Penny Stocks With Market Caps Of US$400M
In the backdrop of fluctuating global trade policies and easing inflation rates, Asian markets are navigating a complex economic landscape. Amid these conditions, penny stocks—often seen as relics from past market eras—continue to capture attention for their potential to offer both affordability and growth. These smaller or newer companies can present unique opportunities when they exhibit strong financial health, making them intriguing options for investors seeking untapped potential in the market. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.435 SGD176.3M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.176 SGD35.06M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.21 SGD8.7B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.13 SGD858.72M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.39 HK$50.26B ★★★★★★ Lever Style (SEHK:1346) HK$1.15 HK$725.59M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.99 HK$1.66B ★★★★★★ Click here to see the full list of 1,159 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★★ Overview: UNQ Holdings Limited operates as a brand e-commerce retail and wholesale solutions provider in the People's Republic of China, with a market cap of HK$588.93 million. Operations: The company generates revenue through various channels, including CN¥478.70 million from B2B General Trade, CN¥421.56 million from B2C General Trade, CN¥11.58 million from services rendered, CN¥170.31 million from B2B Cross-Border E-Commerce, and CN¥266.26 million from B2C Cross-Border E-Commerce. Market Cap: HK$588.93M UNQ Holdings, with a market cap of HK$588.93 million, has shown financial improvements by becoming profitable in the past year, generating CN¥1.35 billion in sales for 2024 compared to CN¥1.74 billion previously and achieving a net income of CN¥37.89 million versus a prior net loss. Despite its low Return on Equity at 5.1%, the company maintains strong liquidity with short-term assets exceeding liabilities and cash surpassing total debt levels, indicating solid financial management amidst volatility concerns. The board's recent restructuring aligns with strategic governance adjustments as UNQ prepares to release its Q1 2025 results shortly. Click here and access our complete financial health analysis report to understand the dynamics of UNQ Holdings. Gain insights into UNQ Holdings' historical outcomes by reviewing our past performance report. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Sipai Health Technology Co., Ltd. is a medical technology and health management company operating in the People's Republic of China with a market cap of HK$2.93 billion. Operations: The company's revenue is primarily derived from its Specialty Pharmacy Business, which generated CN¥3.97 billion, followed by the Physician Research Assistance Business at CN¥397.61 million, and the Health Insurance Services Business contributing CN¥192.96 million. Market Cap: HK$2.93B Sipai Health Technology, with a market cap of HK$2.93 billion, remains unprofitable despite generating CN¥4.57 billion in revenue for 2024, slightly down from the previous year. The company reported a net loss of CN¥323.74 million and has not diluted shareholders recently. Its short-term assets exceed both short- and long-term liabilities significantly, reflecting strong liquidity management alongside being debt-free. While Sipai's cash runway is sufficient for over three years if free cash flow continues to grow historically, its negative Return on Equity highlights ongoing profitability challenges amidst stable weekly volatility and an experienced management team averaging 5.7 years tenure. Unlock comprehensive insights into our analysis of Sipai Health Technology stock in this financial health report. Examine Sipai Health Technology's past performance report to understand how it has performed in prior years. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: ValueMax Group Limited is an investment holding company involved in pawnbroking, moneylending, jewelry and watches retailing, and gold trading primarily in Singapore, with a market capitalization of SGD528.32 million. Operations: The company's revenue is primarily derived from the retail and trading of jewellery and gold, generating SGD343.78 million, followed by pawnbroking at SGD82.01 million and moneylending contributing SGD63.46 million. Market Cap: SGD528.32M ValueMax Group, with a market cap of SGD528.32 million, has shown strong earnings growth, increasing by 56.7% over the past year, surpassing its five-year average of 19.4%. Despite high net debt to equity at 129.9%, short-term assets comfortably cover both short- and long-term liabilities. The company recently launched a digital securities issuance on the SDAX Exchange to raise funds between SGD5 million and SGD25 million at an interest rate of 3.9% per annum, reflecting active financial management strategies amidst stable weekly volatility and experienced leadership with an average tenure of 3.4 years in management and 4.8 years on the board. Click here to discover the nuances of ValueMax Group with our detailed analytical financial health report. Understand ValueMax Group's track record by examining our performance history report. Click through to start exploring the rest of the 1,156 Asian Penny Stocks now. Ready For A Different Approach? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2177 SEHK:314 and SGX:T6I. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
02-06-2025
- Business
- Yahoo
3 Asian Penny Stocks With Market Caps Under US$2B
As global markets navigate the complexities of trade policies and economic fluctuations, investors are keeping a close watch on opportunities across various sectors. In this context, penny stocks—often representing smaller or newer companies—remain an intriguing area for potential growth. Despite being considered a somewhat outdated term, these stocks can offer significant upside when backed by strong fundamentals and robust balance sheets. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.178 SGD35.46M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.12 SGD8.34B ★★★★★☆ BRC Asia (SGX:BEC) SGD3.12 SGD855.97M ★★★★★★ Ever Sunshine Services Group (SEHK:1995) HK$1.91 HK$3.3B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.31 HK$49.34B ★★★★★★ Lever Style (SEHK:1346) HK$1.14 HK$719.28M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.97 HK$1.64B ★★★★★★ Click here to see the full list of 1,161 stocks from our Asian Penny Stocks screener. Let's dive into some prime choices out of the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Shengjing Bank Co., Ltd. operates in Mainland China, providing banking products and related financial services, with a market cap of HK$9.06 billion. Operations: Shengjing Bank's revenue is primarily derived from Corporate Banking, which contributes CN¥4.67 billion, followed by Retail Banking at CN¥1.87 billion and Treasury Business at CN¥176.56 million. Market Cap: HK$9.06B Shengjing Bank, with a market cap of HK$9.06 billion, primarily generates revenue from Corporate Banking (CN¥4.67 billion) and Retail Banking (CN¥1.87 billion). Despite having high-quality earnings and appropriate loan levels, the bank faces challenges with declining net interest income and net income year-over-year. The bank's return on equity is low at 0.8%, and it has a high level of bad loans at 2.7%. Recent board changes include the resignation of Mr. Wang Jun due to retirement, while Mr. Li Weiming has been nominated as a non-executive director candidate for the board's eighth session. Get an in-depth perspective on Shengjing Bank's performance by reading our balance sheet health report here. Learn about Shengjing Bank's historical performance here. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Linklogis Inc. is an investment holding company that provides supply chain finance technology and data-driven solutions in China, with a market cap of HK$2.78 billion. Operations: The company's revenue segments include CN¥663.66 million from Supply Chain Finance Technology Solutions - Anchor Cloud, CN¥306.89 million from FI Cloud within the same category, CN¥51.06 million from Emerging Solutions - Cross-Border Cloud, and CN¥9.57 million from SME Credit Tech Solutions. Market Cap: HK$2.78B Linklogis Inc., with a market cap of HK$2.78 billion, is navigating the challenges of being unprofitable while showing potential in its supply chain finance technology sector. The company's revenues reached CN¥1.03 billion for 2024, yet it reported a net loss of CN¥835.38 million, indicating ongoing profitability struggles despite reducing losses by 43.8% annually over five years. The management and board are seasoned with average tenures exceeding four years, providing stability as they propose amendments to corporate governance structures ahead of the June AGM. A special dividend announcement reflects some positive cash flow dynamics amidst these challenges. Unlock comprehensive insights into our analysis of Linklogis stock in this financial health report. Evaluate Linklogis' prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Grand Venture Technology Limited provides precision manufacturing solutions for various industries including semiconductor, life sciences, electronics, aerospace, and medical sectors across Singapore, Malaysia, the United States, China, and internationally with a market cap of SGD313.84 million. Operations: The company generates revenue from three main segments: SGD22.92 million from life sciences, SGD87.84 million from the semiconductor industry, and SGD48.76 million from electronics, aerospace, medical sectors, and others. Market Cap: SGD313.84M Grand Venture Technology Limited, with a market cap of SGD313.84 million, is experiencing robust earnings growth, having doubled its earnings over the past year and exceeding industry averages. The company generates significant revenue from semiconductor (SGD87.84 million), life sciences (SGD22.92 million), and electronics sectors (SGD48.76 million). Despite low return on equity at 8.3%, it has improved profit margins to 7% and reduced its debt-to-equity ratio from 84% to 52.5%. Recent corporate developments include amendments to the company's constitution and a dividend increase, reflecting strategic adjustments in governance and shareholder returns amidst market volatility. Click to explore a detailed breakdown of our findings in Grand Venture Technology's financial health report. Explore Grand Venture Technology's analyst forecasts in our growth report. Discover the full array of 1,161 Asian Penny Stocks right here. Contemplating Other Strategies? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:2066 SEHK:9959 and SGX:JLB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
30-05-2025
- Business
- Yahoo
Asian Penny Stocks With Market Caps At Least US$200M
As global markets navigate through volatility and trade tensions, Asian markets are under the spotlight for their resilience and growth potential. Penny stocks, a term that may seem outdated yet remains relevant, represent an intriguing investment area within these dynamic economies. By focusing on financial strength and long-term potential, this article explores several penny stocks in Asia that could offer surprising value to investors seeking opportunities in smaller or newer companies. Name Share Price Market Cap Financial Health Rating Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC) THB1.79 THB751.8M ★★★★★★ Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.425 SGD172.25M ★★★★★☆ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.09 SGD8.23B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.93 HK$3.34B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.50 HK$51.52B ★★★★★★ Lever Style (SEHK:1346) HK$1.19 HK$750.83M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.27 HK$2.12B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.95 HK$1.62B ★★★★★★ Click here to see the full list of 1,157 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Huanxi Media Group Limited is an investment holding company involved in the media and entertainment sectors in China and Hong Kong, with a market cap of HK$1.68 billion. Operations: The company generates revenue from its investment in film and TV programmes rights, amounting to HK$34.18 million. Market Cap: HK$1.68B Huanxi Media Group, operating in the media and entertainment sectors in China and Hong Kong, has a market cap of HK$1.68 billion but reported a significant drop in revenue to HK$34.18 million for 2024, compared to HK$1.33 billion the previous year. The company is unprofitable with a net loss of HK$260.82 million for 2024, attributed partly to delayed film releases expected to debut in 2025. Despite having more cash than debt and covering both short- and long-term liabilities with assets totaling HK$1.2 billion, it faces challenges with less than a year of cash runway if current free cash flow trends continue. Navigate through the intricacies of Huanxi Media Group with our comprehensive balance sheet health report here. Gain insights into Huanxi Media Group's outlook and expected performance with our report on the company's earnings estimates. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Sihuan Pharmaceutical Holdings Group Ltd. is an investment holding company involved in the research, development, manufacture, marketing, and sale of pharmaceutical and medical aesthetic products in China, with a market cap of HK$8.69 billion. Operations: The company's revenue is derived from three main segments: Generic Medicine contributing CN¥1.10 billion, Medical Aesthetic Products generating CN¥744.22 million, and Innovative Medicine and Other Medicine adding CN¥109.67 million. Market Cap: HK$8.69B Sihuan Pharmaceutical Holdings Group, with a market cap of HK$8.69 billion, is navigating the challenges of unprofitability while leveraging its robust product pipeline in China's pharmaceutical and medical aesthetic sectors. Recent approvals for its PLLA and PCL fillers position it uniquely within the regenerative medical aesthetics market, potentially enhancing revenue streams as these products gain traction. Despite reporting a net loss of CN¥216.66 million for 2024, the company maintains strong short-term liquidity with assets exceeding liabilities and more cash than debt. The approval of Dapagliflozin Tablets further strengthens its diabetes treatment portfolio, offering potential growth avenues despite current financial setbacks. Click here to discover the nuances of Sihuan Pharmaceutical Holdings Group with our detailed analytical financial health report. Gain insights into Sihuan Pharmaceutical Holdings Group's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Tianjin Chase Sun Pharmaceutical Co., Ltd is involved in the research, development, production, and sale of pharmaceutical products both in China and internationally, with a market cap of CN¥11.42 billion. Operations: No specific revenue segments are reported for Tianjin Chase Sun Pharmaceutical Co., Ltd. Market Cap: CN¥11.42B Tianjin Chase Sun Pharmaceutical, with a market cap of CN¥11.42 billion, is experiencing significant challenges in earnings growth, having reported negative earnings growth over the past year. Despite this, the company maintains strong liquidity with short-term assets of CN¥6.1 billion exceeding both short and long-term liabilities. The management team and board are considered experienced with average tenures of 2.1 and 3.2 years respectively. Recent dividend affirmations indicate some level of shareholder returns, although the dividend yield remains low at 0.79%. The company's debt is well covered by operating cash flow and interest payments by EBIT, reflecting solid financial health amidst volatility in profit margins. Take a closer look at Tianjin Chase Sun PharmaceuticalLtd's potential here in our financial health report. Review our growth performance report to gain insights into Tianjin Chase Sun PharmaceuticalLtd's future. Access the full spectrum of 1,157 Asian Penny Stocks by clicking on this link. Looking For Alternative Opportunities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include SEHK:1003 SEHK:460 and SZSE:300026. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Yahoo
28-05-2025
- Business
- Yahoo
Asian Penny Stocks To Consider In May 2025
As global markets face volatility and economic uncertainties, the Asian stock market continues to capture attention with its unique dynamics and opportunities. Penny stocks, often associated with smaller or newer companies, remain a relevant investment area despite being considered somewhat outdated. By focusing on those with robust financials and growth potential, investors can uncover hidden gems that offer stability alongside promising prospects for growth. Name Share Price Market Cap Financial Health Rating Halcyon Technology (SET:HTECH) THB2.66 THB798M ★★★★★★ CNMC Goldmine Holdings (Catalist:5TP) SGD0.43 SGD174.27M ★★★★★☆ YKGI (Catalist:YK9) SGD0.096 SGD40.8M ★★★★★★ Beng Kuang Marine (SGX:BEZ) SGD0.179 SGD35.66M ★★★★★★ Yangzijiang Shipbuilding (Holdings) (SGX:BS6) SGD2.08 SGD8.19B ★★★★★☆ Ever Sunshine Services Group (SEHK:1995) HK$1.90 HK$3.28B ★★★★★☆ Bosideng International Holdings (SEHK:3998) HK$4.53 HK$51.86B ★★★★★★ Lever Style (SEHK:1346) HK$1.17 HK$738.21M ★★★★★★ Goodbaby International Holdings (SEHK:1086) HK$1.23 HK$2.05B ★★★★★★ TK Group (Holdings) (SEHK:2283) HK$1.94 HK$1.62B ★★★★★★ Click here to see the full list of 1,167 stocks from our Asian Penny Stocks screener. Here's a peek at a few of the choices from the screener. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: EROAD Limited offers electronic on-board units and software as a service to the transport industry across New Zealand, the United States, and Australia, with a market cap of NZ$252.48 million. Operations: The company has not reported specific revenue segments. Market Cap: NZ$252.48M EROAD Limited, with a market cap of NZ$252.48 million, has shown promising financial performance by achieving profitability recently and reporting sales of NZ$194.4 million for the fiscal year ended March 31, 2025. The company's net income was NZ$1.4 million compared to a net loss the previous year, indicating improved margins. EROAD's debt management is commendable with a reduced debt to equity ratio from 69.8% to 8% over five years and satisfactory net debt levels at 3.8%. However, challenges remain with high share price volatility and an inexperienced board and management team impacting stability perceptions in the penny stock landscape. Unlock comprehensive insights into our analysis of EROAD stock in this financial health report. Review our growth performance report to gain insights into EROAD's future. Simply Wall St Financial Health Rating: ★★★★★★ Overview: China Ding Yi Feng Holdings Limited is a publicly owned investment manager with a market cap of HK$569.92 million. Operations: The company's revenue segment is Investment Holding, which reported a revenue of -HK$245.20 million. Market Cap: HK$569.92M Ding Yi Feng Holdings Group International, with a market cap of HK$569.92 million, is pre-revenue and reported substantial negative revenue of -HK$367.55 million for 2024. Despite its unprofitable status and high volatility compared to other Hong Kong stocks, the company maintains a debt-free position with short-term assets exceeding liabilities significantly. The seasoned board has an average tenure of 8.8 years, which may provide stability amid recent changes like auditor transitions announced in May 2025. While the stock's price remains volatile, sufficient cash reserves suggest operational continuity for over a year without additional funding needs. Click here and access our complete financial health analysis report to understand the dynamics of Ding Yi Feng Holdings Group International. Gain insights into Ding Yi Feng Holdings Group International's past trends and performance with our report on the company's historical track record. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Boustead Singapore Limited is an investment holding company that offers energy engineering, real estate, geospatial, and healthcare technology solutions across various regions worldwide with a market capitalization of SGD560.45 million. Operations: No specific revenue segments are reported for this company. Market Cap: SGD560.45M Boustead Singapore Limited, with a market cap of SGD560.45 million, recently reported full-year sales of SGD527.1 million and net income growth to SGD95.05 million, reflecting improved profit margins from 8.4% to 18%. The company shows financial robustness with cash exceeding total debt and high operating cash flow coverage of debt at 970.2%. Earnings have grown significantly by 48.1% over the past year, surpassing both its five-year average and industry growth rates. While trading below estimated fair value by 44.5%, the stock's dividend track record remains unstable despite strong short-term asset coverage over liabilities. Click here to discover the nuances of Boustead Singapore with our detailed analytical financial health report. Learn about Boustead Singapore's historical performance here. Explore the 1,167 names from our Asian Penny Stocks screener here. Want To Explore Some Alternatives? The latest GPUs need a type of rare earth metal called Dysprosium and there are only 24 companies in the world exploring or producing it. Find the list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NZSE:ERD SEHK:612 and SGX:F9D. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
